Bit Digital Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Bit Digital Inc trades at $1.44 (market cap $471.05M), while Vertex Pharmaceuticals Incorporated trades at $529.79 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 285× Bit Digital Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Bit Digital Inc nearer its low. Which is the better fit depends on your goals.
| BTBT | VRTX | |
|---|---|---|
Market Cap | $471.05M | $134.25B |
Sector | Technology | Health |
52-Week High | $4.22 | $529.65 |
52-Week Low | $1.23 | $376.62 |
Enterprise Value | $760.36M | $128.37B |
Signals from Pluang's Aura AI — not financial advice
BTBT trades at $1.485, up 14.23% in the last 24 hours, but remains in a bearish technical trend. The company reported a net loss of $80.32 million on $113.56 million revenue for 2025, with a negative net income margin of -145.45%. Recent earnings have missed expectations, though analyst consensus is a Buy with a $5.12 average price target.
The outlook is challenged by persistent losses and negative cash flow from operations, offset by strong financing activities. Key risks include execution on profitability and market volatility. The stock presents a high-risk opportunity contingent on the company's ability to reverse its negative earnings trend.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Trailing returns across standard periods
Latest headlines on both assets
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →